Preparation method for human-mouse chimeric monoclonal antibodies of human CD20

A monoclonal antibody, human technology, applied in the field of medicine, can solve the problems of high disease recurrence rate, high drug price, short effective duration and so on

Inactive Publication Date: 2015-08-26
刘景华
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to provide a preparation method of a human-mouse chimeric monoclonal antibody against human CD2

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method for human-mouse chimeric monoclonal antibodies of human CD20
  • Preparation method for human-mouse chimeric monoclonal antibodies of human CD20
  • Preparation method for human-mouse chimeric monoclonal antibodies of human CD20

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0020] The present invention is achieved in the following way: a rituximab, comprising the human-mouse chimeric monoclonal antibody of human CD20 as the active ingredient, sodium citrate, polysorbate 80, sodium chloride, and water for injection.

[0021] further, such as figure 1 As shown, the preparation method of the human-mouse chimeric monoclonal antibody of described human CD20 is:

[0022] S101. Animal selection and immunization: 6-12 weeks of SPF grade female Balb / c mice were used, and the immunization process was the same as that of general serum preparation;

[0023] S102, performing ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method for human-mouse chimeric monoclonal antibodies of human CD20. SPF-level female Balb/c mice 6-12 weeks old are employed, and the immunization flows are the same as immunization flows of general serum preparation; the immuned mice are subjected to pretreatment, B cells and myeloma cells are subjected to cell fusion through a PEG method; HAT is employed for selective culture, hybridomas are obtained; the cell culture supernatant fluid is detected, and positive clone screening is carried out; hybridoma cloning is carried out; cryopreservation and recovery of the hybridomas are carried out; human-mouse chimeric monoclonal antibodies of human CD20 are produced for a large scale. An embodiment employing a small dose of rituximab for treating immune thrombocytopenia supports that combination of rituximab and other medicines may obtain better effects in clinic application compared with a single medicine, has good treatment effects in immune thrombocytopenia treatment, has small adverse reactions, and can be employed as an effective second-line treatment means.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a preparation method of human-mouse chimeric monoclonal antibody of human CD20. Background technique [0002] Immune thrombocytopenia (ITP) is a common relapsing autoimmune disease characterized by decreased platelet count and increased bleeding risk. Although the disease is benign, the patient's quality of life is reduced due to the disease itself or treatment-related adverse effects. [0003] Currently recommended first-line treatment for ITP is mainly glucocorticoids, intravenous immunoglobulin and anti-D immunoglobulin. Second-line treatment mainly includes splenectomy, rituximab, and thrombopoietin receptor agonist (TPO-RA). [0004] The effective rate of glucocorticoids is 60-70%, but hormone dependence is prone to occur in the reduction or continuous medication of the original dose, resulting in a decrease in platelets, and a lot of side effects, such as: high blood pressure, hig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28A61P7/04A61P37/02
Inventor 刘景华
Owner 刘景华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap